Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

BACKGROUND: The PROPKD score has been proposed to stratify the risk of progression to end-stage renal disease in autosomal dominant polycystic kidney disease (ADPKD) subjects. We aimed to assess its prognostic value in a genotyped subgroup of subjects from the Tolvaptan Phase 3 Efficacy and Safety S...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornec-Le Gall, Emilie, Blais, Jaime D, Irazabal, Maria V, Devuyst, Olivier, Gansevoort, Ron T, Perrone, Ron D, Chapman, Arlene B, Czerwiec, Frank S, Ouyang, John, Heyer, Christina M, Senum, Sarah R, Le Meur, Yannick, Torres, Vicente E, Harris, Peter C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888998/
https://www.ncbi.nlm.nih.gov/pubmed/28992127
http://dx.doi.org/10.1093/ndt/gfx188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888998/
https://www.ncbi.nlm.nih.gov/pubmed/28992127
http://dx.doi.org/10.1093/ndt/gfx188

Ejemplares similares